Urmila Kafle

Urmila Kafle

Auto-generated profile, based on publicly available information

Urmila Kafle

Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, United States of America

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
UKUrmila Kafle
Urmila Kafle
HTHoang Quan Truong
Hoang Quan Truong
CNCao Thuy Giang Nguyen
Cao Thuy Giang Nguyen
FMFanfei Meng
Fanfei Meng

13 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
UKUrmila Kafle
Urmila Kafle
SASatish Agrawal
Satish Agrawal
ADAlekha K. Dash
Alekha K. Dash
Breast cancer is the most diagnosed type of cancer, with 2.26 million cases and 685,000 deaths recorded in 2020. If left untreated, this deadly disease can metastasize to distant organs, which is the reason behind its incurability and related deaths. Currently, conventional therapies are used to treat breast cancer, but they have numerous shortcomings such as low bioavailability, short circulation time, and off-target toxicity. To address these challenges, nanomedicines are preferred and are being extensively investigated for breast cancer treatment. Nanomedicines are novel drug delivery systems that can improve drug stability, aqueous solubility, blood circulation time, controlled release, and targeted delivery at the tumoral site and enhance therapeutic safety and effectiveness. Nanoparticles (NPs) can be administered through different routes. Although the injectable route is less preferred than the oral route for drug administration, it has its advantages: it helps tailor drugs with targeted moiety, boosts payload, avoids first-pass metabolism, and improves the pharmacokinetic parameters of the active pharmaceutical ingredients. Targeted delivery of nanomedicine, closer to organelles such as the mitochondria and nuclei in breast cancer, reduces the dosage requirements and the toxic effects of chemotherapeutics. This review aims to provide the current status of the recent advances in various injectable nanomedicines for targeted treatment of breast cancer.

3 December 2025 in Food Bioscience
Verified
Journal Article
Open access
RTRajan Thapa
Rajan Thapa
MSMichael A. Schlesinger
Michael A. Schlesinger
NPNisha Panth
Nisha Panth
NSNewton Suwal
Newton Suwal
SBSaroj Bashyal
Saroj Bashyal
Keshav Raj PaudelKeshav Raj Paudel
Keshav Raj Paudel

26 November 2025 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
UKUrmila Kafle
Urmila Kafle
EMErik Moore
Erik Moore
ALAlexander Lushnikov
Alexander Lushnikov
ADAlekha K. Dash
Alekha K. Dash
Breast cancer is a prevalent malignancy that can metastasize to distant organs if left untreated, leading to significant morbidity. While chemotherapy is commonly used, it has drawbacks like low tissue availability, short circulation time, and toxicity to healthy cells. The objective of this study was to develop and characterize three different nanovesicles loaded with doxorubicin hydrochloride and paclitaxel, hypothesizing that this combination would enhance tumor targeting, reduce dosing and toxicity, and improve patient compliance. A validated UPLC method was developed for simultaneous detection and quantitation of both drugs, showing linearity over 3.13–50 µg/mL. Retention times were 1.53 and 4.06 min for doxorubicin hydrochloride and paclitaxel, respectively. Using thin-film hydration technique, blank and drug-loaded liposomes, transfersomes, and niosomes were formulated. Nanovesicles were characterized for size (150–250 nm), polydispersity index (0.14–0.20), and zeta potential (-0.56 to + 0.54 mV). Drug loading was 2.0–2.5% for doxorubicin hydrochloride and 7.0–7.5% for paclitaxel, with high encapsulation efficiency. Drug release studies showed sustained release for up to 72 h. Nanovesicles remained stable for at least seven days at room temperature and 4⁰C. Cytotoxicity and apoptosis studies using MTT assay and flow cytometry on MDA-MB 231 breast cancer cells revealed that the drug-loaded nanovesicles exhibited potent cytotoxicity and induced apoptotic cell death more effectively than individual drug solutions. In conclusion, this study successfully developed three nanovesicular systems co-loaded with doxorubicin hydrochloride and paclitaxel, demonstrating their potential as effective drug delivery systems for breast cancer treatment. Graphical Abstract Created in BioRender. Dang, L. (2025) https://BioRender.com/h14t77